bupropion has been researched along with Heart Failure in 2 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To calculate incremental cost-utility ratios (cost per quality-adjusted life-year [QALY] gained) for bupropion (Zyban; GlaxoSmithKline; Gothenburg, Sweden), as compared to nicotine replacement therapy (NRT) in smoking cessation programs for a follow-up period of 20 years." | 7.73 | The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. ( Bolin, K; Lindgren, B; Willers, S, 2006) |
| "Bupropion is a new antidepressant of the aminoketone class which is structurally unrelated to the tricyclics and which is relatively free of cardiac side effects in healthy depressed patients." | 6.66 | Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. ( Bigger, JT; Giardina, EG; Glassman, AH; Johnson, LL; Roose, SP; Walsh, BT, 1987) |
| "To calculate incremental cost-utility ratios (cost per quality-adjusted life-year [QALY] gained) for bupropion (Zyban; GlaxoSmithKline; Gothenburg, Sweden), as compared to nicotine replacement therapy (NRT) in smoking cessation programs for a follow-up period of 20 years." | 3.73 | The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. ( Bolin, K; Lindgren, B; Willers, S, 2006) |
| "Bupropion is a new antidepressant of the aminoketone class which is structurally unrelated to the tricyclics and which is relatively free of cardiac side effects in healthy depressed patients." | 2.66 | Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. ( Bigger, JT; Giardina, EG; Glassman, AH; Johnson, LL; Roose, SP; Walsh, BT, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolin, K | 1 |
| Lindgren, B | 1 |
| Willers, S | 1 |
| Roose, SP | 1 |
| Glassman, AH | 1 |
| Giardina, EG | 1 |
| Johnson, LL | 1 |
| Walsh, BT | 1 |
| Bigger, JT | 1 |
1 trial available for bupropion and Heart Failure
| Article | Year |
|---|---|
Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure.
Topics: Aged; Angiocardiography; Antidepressive Agents; Blood Pressure; Bupropion; Clinical Trials as Topic; | 1987 |
1 other study available for bupropion and Heart Failure
| Article | Year |
|---|---|
The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden.
Topics: Adult; Aged; Bupropion; Chewing Gum; Cost-Benefit Analysis; Dopamine Uptake Inhibitors; Female; Hear | 2006 |